




RealRate

PHARMACEUTICAL 2018

CHINOOK THERAPEUTICS INC. Rank 170 of 342





RealRate

PHARMACEUTICAL 2018

CHINOOK THERAPEUTICS INC. Rank 170 of 342



The relative strengths and weaknesses of CHINOOK THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHINOOK THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of CHINOOK THERAPEUTICS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 98%, being 52% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	350,131
Cost of Goods Sold	0
Intangible Assets	39,830
Liabilities, Current	41,401
Liabilities, Non-Current	818
Other Assets	24,082
Other Compr. Net Income	3,577
Other Expenses	-10,805
Other Liabilities	165,436
Other Net Income	3,226
Other Revenues	17,239
Property and Equipment	31,085
Research and Development	89,382
Selling, General and Administrative Expense	33,751

Output Variable	Value in 1000 USD
Assets	445,128
Liabilities	207,655
Expenses	112,328
Revenues	17,239
Stockholders Equity	237,473
Net Income	-91,863
Comprehensive Net Income	-90,074
Economic Capital Ratio	98%